Our study suggests that peripheral blood mSEPT9 can be utilized as an effective biomarker for monitoring recurrence and evaluating prognosis after surgery for CRC and that, combined with CEA testing, can improve the mSEPT9 diagnostic efficacy in the surveillance of recurrence in CRC. The gene discussed is CEACAM5; the disease is colorectal carcinoma.